June 13, 2023
Humanized monoclonal antibody nimotuzumab
The Chinese National Drug Administration approved on Monday the commercialization and use of nimotuzumab, a Cuban humanized monoclonal antibody for the treatment of pancreatic cancer.
The approval is the result of research carried out by the joint venture Biotech Pharmaceutical Limited (BPL) to expand the drug’s application in China beyond nasopharyngeal cancer therapy.
The Chinese health agency referred to the good results of the product in clinical studies, its efficacy in inhibiting the growth of malignant cells and its widespread use since 1998 in Cuba and other nations.
Yanet Borrego, deputy general manager vice-president for the Cuban part of GLP, said “China approved the registration of nimotuzumab to treat pancreatic cancer, after a phase III clinical study”.
One of the main advantages of nimotuzumab is that it preferentially recognizes tumor cells and not normal tissue, allowing it to be combined with radiotherapy and chemotherapy, or exclusively.
BPL President Bai Xianhong informed Cuban Vice Prime Minister Jorge Luis Perdomo in April about research on the effect of nimotuzumab in the treatment of other types of cancers.
Source: Cubadebate, translation Resumen Latinoamericano – English